Epidermal growth factor receptor targeted therapies for solid tumours

Acta Clinica Belgica

Volumn 66, Issue 1, 2011, Pages 10-17

  Van Den Eynde, M ^a   Baurain, J F ^a   Mazzeo, F ^a   Machiels, Jean Pascal ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

Efficacy; EGFR targeted therapies; Predictive factors; Solid tumours

Indexed keywords

ANTINEOPLASTIC AGENT; B RAF KINASE; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CARMUSTINE; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GEMCITABINE; IRINOTECAN; K RAS PROTEIN; LAPATINIB; METHOTREXATE; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PLATINUM DERIVATIVE; TEMOZOLOMIDE; ZALUTUMUMAB;

ADD ON THERAPY; ADJUVANT THERAPY; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; COLORECTAL CANCER; COPY NUMBER VARIATION; DRUG EFFICACY; DRUG ERUPTION; GENE MUTATION; GLIOBLASTOMA; HEAD AND NECK CARCINOMA; HUMAN; INJECTION SITE REACTION; LUNG NON SMALL CELL CANCER; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MUCOSA INFLAMMATION; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PROGRESSION FREE SURVIVAL; RECEPTOR UPREGULATION; REVIEW; SIGNAL TRANSDUCTION; SKIN TOXICITY; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CELL CYCLE; COLORECTAL NEOPLASMS; GLIOBLASTOMA; HEAD AND NECK NEOPLASMS; HUMANS; LUNG NEOPLASMS; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS B-RAF; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 79952609039     PISSN: 00015512     EISSN: None     Source Type: Journal    
DOI: 10.2143/ACB.66.1.2062508     Document Type: Review

References (51)

1. Ciardello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 2008; 358: 1160-1174.
2. Shepard H, Brdlik C, Schreiber H. Signal integration: a framework for understanding the efficacy of therapeutics targeting the human EGFR family. J Clin Invest 2008; 118: 3574-3581.
3. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003; 21: 2787-2799. (Pubitemid 46606324)
4. Karamouzis MV, Grandis JR, Argiris A. Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas. JAMA 2007; 298: 70-82. (Pubitemid 47026772)
5. Gridelli C, Bareschino MA, Schettino C, Rossi A, Maione P, Ciardiello F. Erlotinib in non-small cell lung cancer treatment: current status and future development. Oncologist 2007; 12: 840-849. (Pubitemid 47328227)
6. Tol J, Punt C. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review. Clin Ther. 2010; 32: 437-453.
7. Sridhar SS, Seymour L, Shepherd FA. Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer. Lancet Oncol 2003; 4: 397-406. (Pubitemid 36833681)
8. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-345. (Pubitemid 38944402)
9. Jonker D, O'Callaghan C, Karapetis C, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007; 357: 2040-2048. (Pubitemid 350106711)
10. Karapetis C, Khambata-Ford S, Jonker D, et al. K-Ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359: 1757-1765.
11. Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer J Clin Oncol 2007; 25: 1658-1664. (Pubitemid 46797944)
12. Amado RG, Wolf M, Peeters M, et al. Wild-type KRas is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 1626-1634.
13. Van Cutsem E, Lang I, Folprecht G, et al. Cetuximab plus FOLFIRI: Final data from the CRYSTAL study on the association of KRas and BRaF biomarker status with treatment outcome. J Clin Oncol 2010; 28 (suppl; abstr 3570): 278s.
14. Bokemeyer C, Bondarenko I, Hartmann J, et al. Biomarkers predictive for outcome in patients with metastatic colorectal cancer treated with first-line FOL-FOX4 plus or minus cetuximab: updated data from the OPUS study. ASCO-GI 2010, poster presentation, abstr 428.
15. Bokemeyer C, Kohne C, Rougier P, et al. Cetuximab with chemotherapy (CT) as first-line treatment for metastatic colorectal cancer (mCRC): Analysis of the CRYSTAL and OPUS studies according to KRAs and BRAF mutation status. J Clin Oncol 2010; 28(15s): (suppl; abstr 3506).
16. Douillard JY, Siena S, Cassidy J. Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study. J Clin Oncol. 2010; 28: 4697-4705.
17. Maughan T, Adams R, Smith C et al. Identification of potentially responsive subsets when cetuximab is added to oxaliplatin-fluoropyrimidine chemotherapy (CT) in first-line advanced colorectal cancer (aCRC): Mature results of the MRC COIN trial. J Clin Oncol 2010; 28(suppl; abstr 3502): 261s.
18. Tol J, Koopman M, Cats A et al. Chemotherapy, bevacizumab and cetuximab in metastatic colorectal cancer. N Engl J Med 2009; 360: 563-572.
19. Hecht J, Mitchell E, Chidiak T, et al. A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer. J Clin Oncol 2009; 27: 672-680.
20. Peeters M, Price T, Cervantes A, et al. Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer. J Clin Oncol. 2010; 28: 4706-4713.
21. Langer C, Kopit J, Awad M, et al. Analysis of KRAS mutation in patients with metastatic colorectal cancer receiving cetuximab in combination irinotecan: results from the EPIC trial. Ann Oncol 2008; 19(suppl 8): 385P.
22. Alberts S, Sargent D, Smyrk T et al. Adjuvant mFOLFOX6 with or without cetuximab in KRAS wild-type patients with resected stage III colon cancer: Results from NCCTG Intergroup Phase III Trial N0147. J Clin Oncol 2010; 28(18s): suppl; abstr CRA3507.
23. Philipp J, Benedetti J, Corless C, et al. Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Group-Directed Intergroup Trial S0205. J Clin Oncol 2010; 28: 3605-3610.
24. Moore M, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer : a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25: 1960-1966. (Pubitemid 46972777)
25. Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353: 123-132. (Pubitemid 41058344)
26. Gatzemeier U, Pluzanska A, Szczesna A et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol. 2007; 25: 1545-1552. (Pubitemid 46733081)
27. Herbst RS, Prager D, Hermann R et al. TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005; 23: 5892-5899
28. Thatcher N, Natale R, herbst R, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small cell lung cancer: results from a randomized, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005; 366: 1527-1537. (Pubitemid 41540110)
29. Giaccone G, Herbst RS, Manegold C et al. Gefitinib in combination with gemcitabine and cispatin in advanced non-small-cell lung cancer: A phase III trial-INTACT 1. J Clin Oncol 2004; 22: 777-784. (Pubitemid 41103588)
30. Herbst RS, Giaccone G, Schiller JH et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT 2. J Clin Oncol 2004; 22: 785-794. (Pubitemid 41103589)
31. Pirker R, Szczesna A, von Pawel J, et al. FLEX: A randomized, multicenter, phase III study of cetuximab in combination with cisplatin/vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2008; 26: May 20 suppl; abstr 3.
32. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus Cetuximab for Squamous Cell Carcinoma of the Head and Neck. N Engl J Med 2006 ; 354 : 567-578. (Pubitemid 43209104)
33. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010; 11: 21-28.
34. Vermorken J, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Eng J Med 2008; 11: 1116-1127.
35. Vermorken JB, Stöhlmacher J, Davidenko I et al. Primary efficacy and safety results of SPECTRUM, a phase 3 trial in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without panitumumab. Annals of Oncology 2010 (Suppl 8): LBA26.
36. Machiels JP, Subramian S, Ruzsa A, et al. An open-label, randomized phase III trial of zalutumumab, a human monoclonal EGF receptor (EGFR) antibody, versus best supportive care in patients with non-curable squamous cell carcinoma (SCCHN) of the head and neck who have failed standard platinum-based therapy. J Clin Oncol 2010 ; 28(suppl): LBA5506 (abstr.).
37. Stewart JS, Cohen EE, Licitra L, et al. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2009; 27: 1864-1871.
38. Argiris A, Ghebremichael M, Gilbert J, Burtness B, Forastiere A. A phase III randomized, placebo-controlled trial of docetaxel (D) with or without gefitinib (G) in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): A trial of the Eastern Cooperative Oncology Group (ECOG). J Clin Oncol 2009; 27(suppl): 6011 (abstr).
39. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009; 10: 459-466.
40. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008; 321: 1807-1812.
41. Frederick L, Wang XY, Eley Gea. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastoma. Cancer Res. 2000; 60: 1383-1387. (Pubitemid 30152011)
42. van den Bent MJ, Brandes AA, Rampling R, et al. Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. J Clin Oncol. 2009; 27: 1268-1274.
43. Mellinghoff IK, Wang MY, Vivanco I, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med. 2005; 353: 2012-2024. (Pubitemid 41609094)
44. Rich JN, Rasheed BK, Yan H. EGFR mutations and sensitivity to gefitinib. N Engl J Med. 2004; 351: 1260-1261
45. Stommel JM, Kimmelman AC, Ying H, et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science. 2007; 318: 287-290. (Pubitemid 47574858)
46. De Roock W, Jonker D, Di Nicolantonio F, et al. Association of KRas p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 2010; 304: 1812-1820.
47. Douillard J, Shepherd F, Hirsh V, et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol 2010 ; 28: 744-752.
48. De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010; 11: 753-762.
49. Sharma S, Bell D, Settleman J, et al. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007; 7: 169-181.
50. Sequist L, Bell D, Lynch T, et al. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung canecr. J Clin Oncol 2007; 25: 587-9551.
51. Tsao M, Sakurada A, Cutz J, et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 2005; 353: 133-144. (Pubitemid 41058345)